Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Neurofibromatosis 1 7Neurofibroma, Plexiform 4Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Pancreatic Neoplasms 1Pain 1Neurofibrosarcoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

AZD 6244 4trametinib 2mirdametinib 2dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neurofibroma, Plexiform × AZD 6244 × 90 days × Clear all
NCT01362803 2026-06-01

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
99 enrolled 1 FDA
CNS

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT06188741 2026-05-29

NF114

University of Alabama at Birmingham

Phase 2 Recruiting
200 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04590235 2026-05-14

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

AstraZeneca

Phase 1 Active not recruiting
32 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04924608 2026-03-23

KOMET

AstraZeneca

Phase 3 Active not recruiting
145 enrolled 17 charts 1 FDA
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡